Plain-English translation of NCT06084819 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing venetoclax—a newer medication—combined with four other drugs (azacitidine, cytarabine, aclarubicin, and chidamide) plus a growth factor to see if it works better than standard therapy for acute myeloid leukemia (AML) that has returned or stopped responding to previous treatment. The study will compare how well this medication combination helps patients compared to the best available standard treatments currently used.
Patients with AML that comes back or stops responding to initial treatment have very poor outcomes, with typical survival of only 4 to 7 months. Researchers believe that combining this medication with other drugs that work through different mechanisms might help more patients respond better and live longer.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will be randomly assigned to receive either the new medication combination or standard best available therapy. Those in the new treatment group will receive the six medications through carefully scheduled dosing over 14 days, with growth factor injections continuing until your blood counts recover. You will have regular visits to monitor your response and manage any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China